Briacell Therapeutics Corp
BCTXW0.170USD
+0.019+13.34%
Close 04/24, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Briacell Therapeutics Corp Company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
Company codeBCTXW
Company nameBriacell Therapeutics Corp
IPO dateOct 12, 2006
Founded at2006
CEODr. William V. Williams, M.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
AddressSuite 300 - Bellevue Centre, 235 -15th Street
CityWEST VANCOUVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV7T 2X1
Phone16049211810
Websitehttps://briacell.com/
Company codeBCTXW
IPO dateOct 12, 2006
Founded at2006
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
--
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
--
--
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
--
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Type
Shareholder
Proportion
Other
100.00%
Institutional Shareholding
Update time: Sat, Feb 22
Update time: Sat, Feb 22
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
7
457.21K
0.00%
-201.44K
2024Q4
9
457.21K
0.00%
-724.11K
2024Q3
9
479.86K
0.00%
-682.43K
2024Q2
9
460.82K
0.00%
-691.44K
2024Q1
10
495.80K
0.00%
-700.81K
2023Q4
9
495.00K
0.00%
-701.61K
2023Q3
9
540.14K
0.00%
-656.33K
2023Q2
9
673.79K
0.00%
-638.16K
2023Q1
8
787.84K
0.00%
-758.62K
2022Q4
8
1.55M
0.00%
+35.90K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
375.00K
0%
--
--
Dec 31, 2024
Redmond Asset Management, LLC
75.00K
0%
--
--
Dec 31, 2024
UBS Financial Services, Inc.
6.41K
0%
-22.64K
-77.93%
Dec 31, 2024
Osaic Holdings, Inc.
800.00
0%
--
--
Dec 31, 2024
Privium Fund Management BV
--
0%
-64.91K
-100.00%
Sep 30, 2023
Sequoia Financial Group, LLC
--
0%
-45.00K
-100.00%
Dec 31, 2023
K. J. Harrison & Partners, Inc.
--
0%
-68.89K
-100.00%
Sep 30, 2023
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data